|
T6154 |
SU11274
|
Met Kinase Inhibitor,PKI-SU11274 |
Apoptosis
,
VEGFR
,
FGFR
,
c-Met/HGFR
,
CDK
,
Autophagy
|
|
SU11274 (Met Kinase Inhibitor)(IC50=10 nM) is a specific Met inhibitor. It shows no significant effects on PGDFRβ, EGFR or Tie2. |
|
T9123 |
DS-1205
|
|
TAM Receptor
|
|
DS-1205 is a potent and selective inhibitor of AXL kinase, with an IC50 of 1.3 nM. DS-1205 also inhibits MER, MET, and TRKA, with IC50s of 63, 104, and 407 nM, respectively. DS-1205 can inhibit cell migration in vitro an... |
|
T1661 |
Crizotinib
|
PF-02341066 |
c-Met/HGFR
,
ROS
,
ALK
,
Autophagy
,
ROS Kinase
|
|
Crizotinib (PF-02341066) is an ATP-competitive small-molecule tyrosine kinases inhibitor of c-MET (IC50: 8 nM) and ALK (IC50: 20 nM) receptor. |
|
T3455 |
Merestinib
|
LY2801653 |
Discoidin Domain Receptor (DDR)
,
FLT
,
c-Met/HGFR
,
ROS
,
ROS Kinase
|
|
Merestinib (LY2801653) is an orally available, small molecule inhibitor of the proto-oncogene c-Met (Ki: 2 nM) with potential antineoplastic activity. Merestinib electively binds to c-Met, thereby inhibiting c-Met phosph... |
|
T3550 |
X-376
|
Ensartinib,X-396 |
c-Met/HGFR
,
ALK
|
|
X-376 (Ensartinib) is an orally available small molecule inhibitor of the receptor tyrosine kinase anaplastic lymphoma kinase (ALK) with potential antineoplastic activity. Upon oral administration, X-396 binds to and inh... |
|
T8399 |
Crizotinib hydrochloride
|
PF-02341066 hydrochloride |
c-Met/HGFR
,
ROS
,
ALK
,
Autophagy
,
ROS Kinase
|
|
Crizotinib hydrochloride (PF-02341066 hydrochloride) is a novel inhibitor of anaplastic lymphoma kinase and c-Met(IC50s of 20 and 8 nM) |
|
T2054 |
Altiratinib
|
DCC-2701 |
VEGFR
,
Tie-2
,
FLT
,
Trk receptor
,
c-Met/HGFR
|
|
Altiratinib (DCC-2701)(DCC-2701) is a novel c-MET/TIE-2/VEGFR inhibitor; effectively reduce tumor burden in vivo and block c-MET pTyr(1349)-mediated signaling, cell growth and migration as compared with an HGF antagonist... |
|
T22324 |
Ensartinib hydrochloride
|
Ensartinib dihydrochloride,X-396 dihydrochloride |
Others
,
Trk receptor
,
c-Met/HGFR
,
ALK
|
|
Ensartinib hydrochloride (X-396 dihydrochloride) is a potent new-generation ALK inhibitor with high activity against CNS metastases and a broad range of known crizotinib-resistant ALK mutations. It potently inhibits both... |
|
T17184 |
Tyrosine kinase inhibitor
|
|
c-Met/HGFR
,
Tyrosine Kinases
|
|
Tyrosine kinase inhibitor is a tyrosine kinase inhibitor used in combination with fragmenting aromatic nitrogen compounds as antiproliferative agents. |
|
T2516 |
Amuvatinib
|
MP470,HPK 56 |
Apoptosis
,
FLT
,
c-Met/HGFR
,
c-RET
,
DNA/RNA Synthesis
,
PDGFR
,
c-Kit
|
|
Amuvatinib (MP470) is an orally bioavailable synthetic carbothioamide with potential antineoplastic activity. |
|
T2586 |
Cabozantinib
|
XL184,BMS-907351 |
Apoptosis
,
VEGFR
,
FLT
,
c-Met/HGFR
,
c-RET
,
TAM Receptor
,
c-Kit
|
|
Cabozantinib (XL184) is a multi-targeted tyrosine kinase receptor inhibitor that inhibits VEGFR2, c-Met, Kit, Axl, and Flt3 (IC50=0.035/1.3/4.6/7/11.3 nM). Cabozantinib exhibits both antitumor and antiangiogenic activity... |
|
T21312 |
Afatinib
|
Afatinib free base,BIBW 2992 |
EGFR
,
Autophagy
|
|
Afatinib (BIBW 2992) is an irreversible inhibitor of EGFR family (EGFR-wt, EGFR-L858R, EGFR-L858R/T790M and HER2 with IC50s of 0.5 nM, 0.4 nM, 10 nM and 14 nM , respectively). |
|
T5164 |
Cabozantinib hydrochloride
|
XL184,Cabozantinib hydrochloride (849217-68-1(free base)),BMS-907351 |
VEGFR
,
FLT
,
c-Met/HGFR
,
TAM Receptor
,
c-Kit
,
ROR
|
|
Cabozantinib hydrochloride (XL184) is a potent pan-tyrosine kinases inhibitor that inhibits VEGFR2, c-Met, Kit, Axl, and Flt4 (IC50s: 0.035, 1.3, 4.6, 7 and 6 nM). |
|
T1773 |
Afatinib Dimaleate
|
BIBW2992,Afatinib,BIBW 2992MA2,Afatinib (BIBW2992) Dimaleate |
EGFR
,
HER
,
Autophagy
|
|
Afatinib Dimaleate (BIBW 2992MA2) is an orally bioavailable anilino-quinazoline derivative and inhibitor of the receptor tyrosine kinase (RTK) epidermal growth factor receptor (ErbB; EGFR) family, with antineoplastic act... |
|
T67859 |
C-Met inhibitor D9
|
|
c-Met/HGFR
|
|
C-Met inhibitor D9 is a c-Met kinase inhibitor. |
|
T3209 |
AMG-337
|
AMG337 |
c-Met/HGFR
|
|
AMG-337 is an effective and highly specific ATP-competitive MET kinase inhibitor. In enzymatic assays, AMG-337(AMG337) inhibits MET kinase activity (IC50: < 5 nM). |
|
T8326 |
BMS-2
|
|
VEGFR
,
FLT
,
c-Met/HGFR
|
|
BMS-2 is a Met/Flt-3/VEGFR2 tyrosine kinase inhibitor. |
|
T5467 |
SAR125844
|
SAR125884 |
Apoptosis
,
c-Met/HGFR
|
|
SAR125844, a potent and highly selective inhibitor of the MET receptor tyrosine kinase (RTK), for intravenous administration. (IC50 value of 4.2 nmol/L) |
|
T7900 |
BAY-474
|
|
c-Met/HGFR
|
|
BAY-474 is an inhibitor of tyrosine-protein kinase c-Met. It acts as an epigenetics probe |
|
T2676 |
PF-04217903
|
|
c-Met/HGFR
|
|
MET Tyrosine Kinase Inhibitor PF-04217903 is an orally bioavailabe, small-molecule tyrosine kinase inhibitor with potential antineoplastic activity. |
|
T6121 |
Tepotinib
|
EMD-1214063,MSC2156119 |
Trk receptor
,
c-Met/HGFR
,
TAM Receptor
|
|
Tepotinib (EMD-1214063) is an inhibitor of MET tyrosine kinase with potential antineoplastic activity. |
|
T15617 |
JNJ-38877618
|
OMO-1 |
c-Met/HGFR
|
|
JNJ-38877618 (OMO-1) is an effective and highly selective inhibitor of Met kinase (IC50s: 2 and 3 nM for wild type and mutant Met, respectively). |
|
T8409 |
SYN1143
|
RON-IN-1,AMG-1 |
c-Met/HGFR
|
|
SYN1143 (AMG-1) is a potent inhibitor of human RON and c-Met.In vitro kinase assays showed that compound I is a potent inhibitor of human RON and c-Met with IC50s of 9 and 4 nmol/L, respectively. |
|
T3113 |
Foretinib
|
GSK089,EXEL-2880,GSK1363089,XL880 |
VEGFR
,
Tie-2
,
c-Met/HGFR
|
|
Foretinib (GSK1363089) is a broad-spectrum tyrosine kinase inhibitor with IC50s of 0.4 nM and 0.9 nM for Met and KDR. |
|
T5677 |
SAR125884 hydrochlorid (1116743-46-4(free base))
|
|
c-Met/HGFR
|
|
SAR125844 is a potent and selective MET kinase inhibitor with a favorable preclinical toxicity profile,(IC50=4.2 nM). |
|
T6517 |
Golvatinib
|
E-7050 |
VEGFR
,
c-Met/HGFR
|
|
Golvatinib (E-7050) is an orally bioavailable dual kinase inhibitor of c-Met (hepatocyte growth factor receptor) and VEGFR-2 (vascular endothelial growth factor receptor-2) tyrosine kinases with potential antineoplastic ... |
|
T5414 |
Glumetinib
|
SCC244 |
c-Met/HGFR
|
|
Glumetinib (SCC244) (SCC 244) is a novel potent and selective inhibitor of c-Met kinase (IC50: 0.42 nM). |
|
TQ0041 |
Ningetinib Tosylate
|
|
VEGFR
,
c-Met/HGFR
,
TAM Receptor
|
|
Ningetinib Tosylate is an orally bioavailable tyrosine kinase inhibitor with IC50s of <1.0, 1.9 and 6.7 nM for Axl, VEGFR2, and c-Met, respectively. |
|
TQ0021 |
Ningetinib
|
CT-053,CT053PTSA |
VEGFR
,
c-Met/HGFR
,
TAM Receptor
|
|
Ningetinib (CT-053) (CT053PTSA) is an orally bioavailable tyrosine kinase inhibitor with IC50s of <1.0, 1.9 and 6.7 nM for Axl, VEGFR2, and c-Met, respectively. |
|
T63544 |
RIPK3-IN-1
|
|
|
|
RIPK3-IN-1 is a type II RIPK3DFG-out site inhibitor (IC50: 9.1 nM) that inhibits RIPK1 (IC50: 5.5 μM) and RIPK2 (IC50>10 μM). RIPK3-IN-1 is a c-Met kinase inhibitor (IC50: 1.1 μM). |
|
T10585 |
Bozitinib
|
CBT-101,PLB-1001 |
c-Met/HGFR
|
|
Bozitinib (PLB-1001) (PLB-1001) is a highly selective inhibitor of the c-MET kinase with blood-brain barrier permeability. Bozitinib binds to the conventional ATP-binding pocket of the tyrosine kinase superfamily. |
|
T6351 |
MGCD-265 analog
|
MGCD-265,Glesatinib |
Apoptosis
,
VEGFR
,
c-Met/HGFR
|
|
MGCD-265 analog (Glesatinib) is an orally bioavailable multitargeted tyrosine kinase inhibitor with potential antineoplastic activity with IC50 of 29 nM and 10 nM for c-Met and VEGFR2, respectively. |
|
T8416 |
Capmatinib xHCl
|
INCB28060,Capmatinib hydrochloride(free base),INC280 |
c-Met/HGFR
|
|
Capmatinib xHCl (INCB28060) is a potent, orally active, selective, and ATP competitive c-Met kinase inhibitor, potently blocking in vitro kinase activity (IC50 = 0.13 nM) as well as constitutive or HGF-stimulated activit... |
|
T4260 |
Capmatinib 2HCl
|
INC-280 2HCl,INCB28060 2HCl |
c-Met/HGFR
|
|
Capmatinib 2HCl (INC-280 2HCl) is a novel, ATP-competitive inhibitor of c-MET kinase with an IC50 with 0.13 nM.Capmatinib 2HCl exhibits picomolar enzymatic potency and is highly specific for c-MET with more than 10, 000-... |
|
T1828 |
TTP 22
|
|
Casein Kinase
|
|
TTP 22 is a high affinity, ATP-competitive casein kinase 2 (CK2) inhibitor with IC50/Ki of 0.1 uM/40 nM, and shows selectivity >250-fold for CK2 over JNK3, ROCK1, and MET(IC50> 10 uM). |
|
T1797 |
Cabozantinib S-malate
|
Cabozantinib,XL184,Cabozantinib Malate |
Apoptosis
,
VEGFR
,
c-Met/HGFR
,
TAM Receptor
,
c-Kit
|
|
Cabozantinib S-malate (XL184) is the s-malate salt form of cabozantinib, an orally bioavailable, small molecule receptor tyrosine kinase (RTK) inhibitor with potential antineoplastic activity. |
|
T9052 |
XL092
|
CL-092,JUN04542 |
VEGFR
,
c-Met/HGFR
,
TAM Receptor
|
|
XL092 (JUN04542) is an Axl Mer cMet KDR inhibitor for the treatment of Axl and Mer receptor tyrosine kinase- dependent disorders. |
|
T12418 |
PF-04217903 phenolsulfonate
|
|
c-Met/HGFR
|
|
PF-04217903 phenolsulfonate is a potent ATP-competitive inhibitor of c-Met kinase (Ki of 4.8 nM for human c-Met). |
|
T12417 |
PF-04217903 methanesulfonate
|
|
c-Met/HGFR
|
|
PF-04217903 methanesulfonate is a potent ATP-competitive inhibitor of c-Met kinase (Ki of 4.8 nM for human c-Met). |
|
T26379 |
1D-2
|
1D2,1D 2 |
|
|
1D-2 is a highly potent and exquisitely selective inhibitor of the c-Met protein kinase. |
|
T8795 |
met-kinase-in-2
|
1,6-Naphthyridin-4(1H)-one, 5-[[3-fluoro-4-[[7-(2-hydroxy-2-methylpropoxy)-4-quinolinyl]oxy]phenyl]amino]-3-phenyl- |
|
|
MET kinase-IN-2, a selective and potent MET kinase inhibitor, demonstrates oral bioavailability and exhibits an IC50 value of 7.4 nM. It also possesses antitumor activity[1]. |
|
T63309 |
MET kinase-IN-3
|
|
|
|
MET kinase-IN-3 is a potent, orally active MET inhibitor (IC50: 9.8 nM) that exhibits good broad-spectrum anti-proliferative effects on cancer cells. |
|
T15384 |
Glesatinib
|
MGCD265 |
c-Met/HGFR
|
|
Glesatinib is an orally active and potent dual inhibitor of MET/SMO. Glesatinib is also a tyrosine kinase inhibitor. It antagonizes P-glycoprotein mediated multidrug resistance (MDR) in NSCLC. |
|
T63099 |
C-Met-IN-9
|
|
|
|
c-Met-IN-9 is a 4-phenoxypyridine derivative and a c-Met kinase inhibitor (IC50: 12 nM). c-Met-IN-9 induces apoptosis and shows antitumour effects. |
|
T13108L |
Pamufetinib mesylate
|
TAS-115 mesylate,TAS-115 methanesulfonate |
Others
|
|
TAS-115 mesylate is a potent inhibitor of VEGFR and hepatocyte growth factor receptor (c-Met/HGFR)-targeted kinase(IC50s of 30 and 32 nM for rVEGFR2 and rMET, respectively). |
|
T64080 |
C-Met-IN-12
|
|
|
|
c-Met-IN-12 is a selective, orally active type II c-Met kinase inhibitor (IC50: 10.6 nM). c-Met-IN-12 is a high inhibitor of AXL, Mer and TYRO3 kinases (>80% inhibition at 1 μM). c-Met-IN-12 can be used as a scaffold to ... |
|
T79142 |
C-Met-IN-17
|
|
c-Met/HGFR
|
|
c-Met-IN-17 is a potent inhibitor of c-Met kinase, demonstrating an IC50 of 0.031 μM, and is applicable in anticancer research. [1] |
|
T15383 |
Glesatinib hydrochloride
|
MGCD265 hydrochloride |
c-Met/HGFR
|
|
Glesatinib hydrochloride is an orally active and potent dual inhibitor of MET/SMO. Glesatinib hydrochloride is also a tyrosine kinase inhibitor. It antagonizes P-glycoprotein mediated multidrug resistance (MDR) in NSCLC. |
|
T68740 |
NVP-TAC544
|
|
|
|
NVP-TAC544 is a novel focal adhesion kinase (FAK) inhibitor, potently blocking kinase activity of FAK along with Aurora A, activated Cdc42-associated kinase 1 (ACK1), Met, insulin receptor (IR), TrkA, and IGF-1R. |
|
T71636 |
Golvatinib tartrate
|
|
|
|
Golvatinib tartrate is an orally bioavailable dual kinase inhibitor of c-Met (hepatocyte growth factor receptor) and VEGFR-2 (vascular endothelial growth factor receptor-2) tyrosine kinases with potential antineoplastic ... |
